Sign In
Buy VRTX
$441.74
+13.40 (+3.13%)
At Close: Jun 04, 2026
This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues
05:30am, Thursday, 09'th Nov 2023
Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment, and that business generates billions of dollars in annual revenue. The biotech has treatment candidate in another indication t
Why you can make Vertex Pharmaceuticals a buy on any pullback
11:26am, Wednesday, 08'th Nov 2023
Shares of Vertex Pharmaceuticals, Inc. NASDAQ: VRTX are down nearly 2% after the company delivered its third-quarter earnings report. The news wasn't particularly bad, although there was a slight miss
4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked
05:50am, Wednesday, 08'th Nov 2023
Vertex's Q3 update could have made some investors at least a little more nervous. However, there are four reasons some might be concerned that are easily debunked.
Vertex (VRTX) Q3 Earnings Beat, Sales Miss, Raises '23 View
09:01am, Tuesday, 07'th Nov 2023
Vertex's (VRTX) third-quarter results reflect a year-over-year increase in revenues. The company raises its net product sales guidance for 2023.
Vertex Pharmaceuticals (VRTX) Tops Q3 Earnings Estimates
06:47pm, Monday, 06'th Nov 2023
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.08 per share, beating the Zacks Consensus Estimate of $3.92 per share. This compares to earnings of $4.01 per share a year ago.
Vertex Pharma misses sales estimates on weak demand for older CF treatments
06:02pm, Monday, 06'th Nov 2023
Vertex Pharmaceuticals missed Wall Street estimates for third-quarter sales on Monday, hurt by weaker-than-expected demand for its older cystic fibrosis (CF) treatments.
Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA
08:05am, Friday, 03'rd Nov 2023
Vertex Pharmaceuticals and CRISPR Therapeutics just met with regulators at the Food and Drug Administration. The discussion was about the safety of their gene therapy candidate called exa-cel.
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
06:47pm, Thursday, 02'nd Nov 2023
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $376.55, representing a +1.95% change from its previous close.
Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patients
05:14pm, Tuesday, 31'st Oct 2023
The decision by an advisory committee may lead to Food and Drug Administration approval of the first treatment for humans that uses the CRISPR gene-editing system.
FDA Advisors Consider Crispr Gene-Editing Treatment for Sickle Cell Anemia
03:43pm, Tuesday, 31'st Oct 2023
Nearly all patients treated so far have been relieved of the blood-clogging crises of the disease.
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
06:48pm, Friday, 27'th Oct 2023
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $355.28, denoting a -1.66% change from the preceding trading day.
Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money
10:15am, Friday, 27'th Oct 2023
Vertex is looking to build on its cystic fibrosis drug franchise with promising new therapies. Lending platform Upstart employs AI and machine learning to evaluate potential borrowers.
This Market-Beating Growth Stock Is Set to Outperform Yet Again in 2024
10:00am, Thursday, 26'th Oct 2023
Large-cap growth stocks with wide economic moats and top-shelf management teams have outperformed this year. Vertex Pharmaceuticals, a rare disease specialist, has been one of the strongest performers
2 Best Healthcare Stocks to Buy Right Now
09:15am, Thursday, 26'th Oct 2023
The stock market may be volatile, but investors don't have to wait on the sidelines. Vertex Pharmaceuticals is forging its own path in the rare disease drug market.
Vertex Pharmaceuticals: Buy at the High?
06:15am, Thursday, 26'th Oct 2023
Vertex is firing on all cylinders, with its billion-dollar cystic fibrosis business booming and its pipeline programs advancing. The company may be about to reach a big milestone: the potential regula
